Suramin
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Suramin
- Molecular weight
- 1,297.3
- Structure (SMILES)
- Cc1ccc(C(=O)Nc2ccc(S(=O)(=O)O)c3cc(S(=O)(=O)O)cc(S(=O)(=O)O)c23)cc1NC(=O)c1cccc(NC(=O)Nc2cccc(C(=O)Nc3cc(C(=O)Nc4ccc(S(=O)(=O)O)c5cc(S(=O)(=O)O)cc(S(=O)(=O)O)c45)ccc3C)c2)c1
- 8 8 carbonylbis imino 3 1 phenylenecarbonylimino 4 methyl 3 1 phenylene carbonylimino bis 1 3 5 naphthalenetrisulfonic acid
- 8 8 ureylenebis m phenylenecarbonylimino 4 methyl m phenylene carbonylimino di 1 3 5 naphthalenetrisulfonic acid
- 8,8'-(CARBONYLBIS(IMINO-3,1-PHENYLENECARBONYLIMINO(4-METHYL-3,1-PHENYLENE)CARBONYLIMINO))BIS-1,3,5-NAPHTHALENETRISULFONIC ACID
- 8,8'-(UREYLENEBIS(M-PHENYLENECARBONYLIMINO(4-METHYL-M-PHENYLENE)CARBONYLIMINO))DI-1,3,5-NAPHTHALENETRISULFONIC ACID
- farma
- Farma
- farma 939
- FARMA-939
- fourneau
- Fourneau
- metaret
- Metaret
- naganol
- Naganol
- nsc 34936
- NSC-34936
- suramin
- Suramin
- Suramin [WHO-DD]
- suramin who dd
- suramine
- Suramine
- CAS registry numbers
- 145-63-1
- ChEMBL ID
- CHEMBL265502
- InChIKey
- FIAFUQMPZJWCLV-UHFFFAOYSA-N
- RxNorm IDs (RxCUI)
- 10256
- FDA ingredient codes (UNII)
- 6032D45BEM
- 5361
- 4261196
- 135973538
- Patents
- 0
- Designations
- 2
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Pharmacology name
- suramin
- Type
- Synthetic organic
- Approval recorded by Guide to Pharmacology
- Yes
- Action
- Activator
- Action type
- ACTIVATOR
- Target
- RyR1
- Gene symbol
- RYR1
- Protein identifier
- P21817
- Action
- Activator
- Action type
- ACTIVATOR
- Target
- RyR2
- Gene symbol
- RYR2
- Protein identifier
- Q92736
- Action
- Antagonist
- Action type
- Antagonist
- Target
- P2Y2 receptor
- Gene symbol
- P2RY2
- Protein identifier
- P41231
- Median affinity
- 4.3
- Affinity units
- pIC50
- Action
- Antagonist
- Action type
- Antagonist
- Target
- P2Y1 receptor
- Gene symbol
- P2RY1
- Protein identifier
- P47900
- Median affinity
- 5.3
- Affinity units
- pKi
- Action
- Antagonist
- Action type
- Antagonist
- Target
- P2X3
- Gene symbol
- P2RX3
- Protein identifier
- P56373
- Median affinity
- 4.83
- Affinity units
- pIC50
- Action
- Antagonist
- Action type
- Antagonist
- Target
- P2Y6 receptor
- Gene symbol
- P2RY6
- Protein identifier
- Q15077
- Median affinity
- 4
- Affinity units
- pKB
- Action
- Antagonist
- Action type
- Antagonist
- Target
- P2Y11 receptor
- Gene symbol
- P2RY11
- Protein identifier
- Q96G91
- Affinity units
- pIC50
- Action
- Antagonist
- Action type
- Antagonist
- Target
- P2Y13 receptor
- Gene symbol
- P2RY13
- Protein identifier
- Q9BPV8
- Median affinity
- 5.6
- Affinity units
- pIC50
Open Targets mechanisms
- Mechanism
- Acidic fibroblast growth factor inhibitor
- Action type
- Inhibitor
- Target
- Fibroblast growth factor 1
- Action type
- Antagonist
- Gene symbol
- P2RY2
- Protein identifier
- P41231
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- Antagonist
- Gene symbol
- P2RY1
- Protein identifier
- P47900
- Organism
- Homo sapiens
- Target development level
- Chemical evidence
- Action type
- Antagonist
- Gene symbol
- P2RY6
- Protein identifier
- Q15077
- Organism
- Homo sapiens
- Target development level
- Chemical evidence
- Action type
- Antagonist
- Gene symbol
- P2RY11
- Protein identifier
- Q96G91
- Organism
- Homo sapiens
- Target development level
- Biological evidence
- Action type
- Antagonist
- Gene symbol
- P2RY13
- Protein identifier
- Q9BPV8
- Organism
- Homo sapiens
- Target development level
- Chemical evidence
Investigated indications
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005225
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005258
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005459
- Highest recorded phase
- 1
- Event
- chest pain
- Reports
- 4
- Reporting signal score
- 11.5054
- Event
- electromyogram abnormal
- Reports
- 1
- Reporting signal score
- 7.73814
Trial references
- NCT01038752
- Calculated partition coefficient (XLogP)
- 1.5
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Heavy atoms
- 86
- Molecular formula
- C51H40N6O23S6
- Monoisotopic mass
- 1296.0469086
- Natural product
- Yes
- Recorded assays
- 1,785
- Active assays
- 275
- Confirmatory
- Other
- Screening
- Antinematodal Agents
- Antineoplastic Agents
- Trypanocidal Agents
Distribution coefficient (LogD)
- Median
- 0.00023
- Mean
- 0.00023
- Minimum
- 0.00023
- Maximum
- 0.00023
- Unit
- unitless
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- LogD
Related records
Trials (21)
- A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder
- A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma
- Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors
- Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer
- Efficacy, Safety and Immunogenicity of Rotavirus RV3 Vaccine (Bio Farma) in Neonates
- Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer
- Fluorouracil and Low-Dose Suramin as Chemosensitization in Treating Patients With Metastatic Renal Cell (Kidney) Cancer
- Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer
- Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer
- Phase I/II, Open Label, Randomized, Safety and Immunogenicity Following DTwP-Hepatitis B-Hib-IPV Vaccine (Bio Farma) in Indonesian Infants
- S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery
- Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Adults and Children (Phase I)
- Study of Suramin in Subjects With Furosemide-Resistant AKI
- Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refractory Non-Small Cell Lung Cancer
- Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer
- Suramin in Treating Patients With Recurrent Bladder Cancer
- Suramin in Treating Patients With Recurrent Primary Brain Tumors
- Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease
- Suramin Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
In development for (2)
- Human African trypanosomiasis Phase 1
- Non-small cell lung carcinoma Phase 2
Targets (1)
- FGF1 Acidic fibroblast growth factor inhibitor